CagriSema, which underperformed expectations in its first Phase 3 test, will be studied at different doses and for longer ...
Novo Nordisk (NVO), the maker of the popular GLP-1 medications Wegovy and Ozempic, said potential tariffs on Europe imposed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback